You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1925 Results
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
Sep 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Neoadjuvant
Jun 2017
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Apr 2018
Regimen
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Aug 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
May 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Sep 2017

Pages